People with newly diagnosed therapy-related acute myeloid leukemia with a favorable risk profile had better relapse-free survival and overall survival vs those with intermediate and adverse risk profiles, according to an analysis involving 301 individuals.

Participants included those with (n=118) and without (n=183) antecedent hematologic disorders (AHD). Investigators followed them for a median of 44 months. Among the results:

• 31% had non-Hodgkin lymphoma as a primary malignancy; 27% had breast cancer, and 16% prostate cancer.

• Median relapse-free survival in patients with AHD was 29 months; it was 10 months in those without AHD.

• Median overall survival was 8 months in both groups.

• Older age, poor performance status, thrombocytopenia, non-favorable cytogenetics, and lack of response adversely impacted overall survival.

• The favorable risk cohort had better relapse-free and overall survival vs those in the intermediate and adverse risk cohorts.

Citation: Sasaki K, Jabbour E, Cortes J, et al. Outcome of patients with therapy-related acute myeloid leukemia with or without an antecedent history of myelodysplasia. [Published online ahead of print August 10, 2016]. Clin Lymphoma Myeloma Leuk. doi:http://dx.doi.org/10.1016/j.clml.2016.08.015.